These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 18316011)

  • 1. [The concept of neuroprotective agents as a treatment modulator in the development of brain diseases].
    Bordet R; Lestage P; Onteniente B;
    Therapie; 2007; 62(6):463-72. PubMed ID: 18316011
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroprotection: Present and future.
    Bordet R; Lestage P; Onteniente B;
    Therapie; 2007; 62(6):473-6. PubMed ID: 18316012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotection in progressive brain disorders.
    Djaldetti R; Lev N; Melamed E
    Isr Med Assoc J; 2003 Aug; 5(8):576-80. PubMed ID: 12929297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug therapies for stroke and traumatic brain injury often display U-shaped dose responses: occurrence, mechanisms, and clinical implications.
    Calabrese EJ
    Crit Rev Toxicol; 2008; 38(6):557-77. PubMed ID: 18615310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. List of drugs in development for neurodegenerative diseases. Update June 2007.
    Pogacić V; Herrling P
    Neurodegener Dis; 2007; 4(6):443-86. PubMed ID: 17934328
    [No Abstract]   [Full Text] [Related]  

  • 6. Neuroprotection: challenges and opportunities.
    Faden AI; Stoica B
    Arch Neurol; 2007 Jun; 64(6):794-800. PubMed ID: 17562927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The adult human brain in preclinical drug development.
    Dragunow M
    Nat Rev Drug Discov; 2008 Aug; 7(8):659-66. PubMed ID: 18617887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translation: case study in failure.
    Johnston SC
    Ann Neurol; 2006 Mar; 59(3):447-8. PubMed ID: 16489618
    [No Abstract]   [Full Text] [Related]  

  • 9. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions.
    Exp Biol Med (Maywood); 2008 Nov; 233(11):vi. PubMed ID: 18957631
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuroprotection and enhancement of neurite outgrowth with small molecular weight compounds from screens of chemical libraries.
    Dwyer DS; Dickson A
    Int Rev Neurobiol; 2007; 77():247-89. PubMed ID: 17178477
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface.
    Ludolph AC; Drory VE
    J Neurol; 2000 Dec; 247 Suppl 6():VI/1. PubMed ID: 19714407
    [No Abstract]   [Full Text] [Related]  

  • 12. [Is good old minocycline a new neuroprotective drug?].
    Melero-Fernández de Mera RM; García-Martínez E; Fernández-Gómez FJ; Hernández-Guijo JM; Aguirre N; Galindo MF; Jordán J
    Rev Neurol; 2008 Jul 1-15; 47(1):31-8. PubMed ID: 18592478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boosting controlled autoimmunity: a new therapeutic target for CNS disorders.
    del Barco DG; Berlanga J; Penton E; Hardiman O; Montero E
    Expert Rev Neurother; 2008 May; 8(5):819-25. PubMed ID: 18457538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using Caenorhabditis elegans models of neurodegenerative disease to identify neuroprotective strategies.
    Kraemer B; Schellenberg GD
    Int Rev Neurobiol; 2007; 77():219-46. PubMed ID: 17178476
    [No Abstract]   [Full Text] [Related]  

  • 15. Improving the efficiency of the development of drugs for stroke.
    Howells DW; Sena ES; O'Collins V; Macleod MR
    Int J Stroke; 2012 Jul; 7(5):371-7. PubMed ID: 22712738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. List of drugs in development for neurodegenerative diseases. Update June 2006.
    Kwon MO; Herrling P
    Neurodegener Dis; 2006; 3(3):148-86. PubMed ID: 16954701
    [No Abstract]   [Full Text] [Related]  

  • 17. List of drugs in development for neurodegenerative diseases. Update September 2005.
    Kwon MO; Herrling P
    Neurodegener Dis; 2005; 2(2):61-108. PubMed ID: 16909049
    [No Abstract]   [Full Text] [Related]  

  • 18. Psychopharmacological neuroprotection in neurodegenerative diseases, part III: criteria-based assessment: a report of the ANPA committee on research.
    Lauterbach EC; Mendez MF
    J Neuropsychiatry Clin Neurosci; 2011; 23(3):242-60. PubMed ID: 21948886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulating the cell's appetite for itself.
    Simonsen A; Stenmark H
    Nat Chem Biol; 2007 Jun; 3(6):304-6. PubMed ID: 17510644
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical trials in neuroprotection.
    Whitcup SM
    Prog Brain Res; 2008; 173():323-35. PubMed ID: 18929119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.